Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Treasury Shares (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Treasury Shares for 10 consecutive years, with $522498.0 as the latest value for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 17.62% to $522498.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $522498.0, a 17.62% increase, with the full-year FY2025 number at $522498.0, up 17.62% from a year prior.
  • Treasury Shares was $522498.0 for Q4 2025 at Cartesian Therapeutics, roughly flat from $523254.0 in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.5 million in Q1 2023 to a low of $394450.0 in Q4 2021.
  • A 5-year average of $984818.7 and a median of $561888.0 in 2021 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: skyrocketed 470.8% in 2021, then tumbled 81.16% in 2024.
  • Cartesian Therapeutics' Treasury Shares stood at $394450.0 in 2021, then surged by 332.39% to $1.7 million in 2022, then grew by 20.37% to $2.1 million in 2023, then tumbled by 78.36% to $444238.0 in 2024, then increased by 17.62% to $522498.0 in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Treasury Shares are $522498.0 (Q4 2025), $523254.0 (Q3 2025), and $533331.0 (Q2 2025).